Antioxidant idebenone-loaded nanoparticles based on chitosan and N-carboxymethylchitosan

被引:38
作者
Amorim, Clarissa de M. [1 ]
Couto, Angelica G. [1 ]
Netz, Daisy J. A. [1 ]
de Freitas, Rilton A. [1 ]
Bresolin, Tania M. B. [1 ]
机构
[1] Univ Vale Itajai, Programa Mestrado Ciencias Farmaceut, Niqfar, BR-88302202 Itajai, SC, Brazil
关键词
Antioxidant; Idebenone; Nanoparticles; Chitosan; N-Carboxymethylchitosan; Spray-dryer; Stability; Mucous membrane irritation; NANOCAPSULES; STABILITY; DELIVERY;
D O I
10.1016/j.nano.2010.06.006
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Nanoparticles based on chitosan (Ch) and N-carboxymethylchitosan (N-CMCh) cross-linked with tripolyphosphate (TPP) were developed by co-drying with idebenone in different polymer-to-drug ratios (1.3:1 to 16: 1) with 20% (wt/wt) colloidal silicon dioxide and tripolyphosphate (0.2 mg/mL). At high ratios (8: 1 and 16: 1) the spray-dried powder showed spherical and dense particles with a size close to 1 mu m, allowing almost complete drug coating by the polymeric system and a high efficiency of drug incorporation (>90% and >80%, for Ch and N-CMCh, respectively). The nanoparticles showed a 10-fold increase of drug stability in comparison with free drug and preserved antioxidant activity in vitro. Compared with the severely irritative free form of idebenone, the nanoparticle formulation showed decreased mucous membrane irritation. These results revealed the potential of Ch and N-CMCh nanoparticles as carriers for a hydrophobic and irritative drug such as idebenone for topical or nasal use. From the Clinical Editor: Chitosan and N-carboxymethylchitosan nanoparticles have potential roles as carriers for hydrophobic and irritative drugs such as the antioxidant idebenone for topical or nasal use. (c) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:745 / 752
页数:8
相关论文
共 36 条
[1]  
[Anonymous], 2009, US PHARM
[2]  
Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
[3]   Pharmacokinetics and metabolism of idebenone in healthy male subjects [J].
Bodmer, Michael ;
Vankan, Pierre ;
Dreier, Manfred ;
Kutz, Klaus W. ;
Drewe, Juergen .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (05) :493-501
[4]  
*BRAS AG NAC VIG S, 2005, GUIA REAL EST EST
[5]  
Broussignac P., 1968, CHIM IND GEN CHIM, V99, P1241
[6]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[7]   Stability-Indicating LC-PDA Method for Determination of Idebenone in Nanoparticles Based on Chitosan and N-Carboxymethylchitosan [J].
de Amorim, Clarissa M. ;
Netz, Daisy J. A. ;
Couto, Angelica G. ;
de Freitas, Rilton A. ;
Bresolin, Tania M. B. .
CHROMATOGRAPHIA, 2009, 70 (9-10) :1411-1415
[8]   NANOCAPSULE-COATED MICROPARTICLES PREPARED IN ONE STEP: CHARACTERIZATION AND IN VITRO DRUG RELEASE PROFILES EVALUATION [J].
Domingues, Gislane Scholze ;
Guterres, Silvia Staniscuaski ;
Ruver Beck, Ruy Carlos ;
Pohlmann, Adriana Raffin .
QUIMICA NOVA, 2008, 31 (08) :1966-1972
[9]  
EDWARD MJ, 1988, CUTANEOUS OCULAR TOX, V187, P194
[10]   Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles [J].
Esmaeili, Farnaz ;
Hosseini-Nasr, Mahdi ;
Rad-Malekshahi, Mazda ;
Samadi, Nasrin ;
Atyabi, Fatemeh ;
Dinarvand, Rassoul .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2007, 3 (02) :161-167